Pharmacology of orismilast, a potent and selective PDE4 inhibitor
Silverberg J, French L, Warren R, Strober B, Kjøller K, Sommer M, Andres P, Felding J, Weiss A, Tutkunkardas D, Skak‐Nielsen T, Guttman E. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 721-729. PMID: 36527389, DOI: 10.1111/jdv.18818.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Inflammatory AgentsCytokinesHumansInflammationLeukocytes, MononuclearMicePhosphodiesterase 4 InhibitorsTumor Necrosis Factor-alphaConceptsChronic inflammatory skin diseasePeripheral blood mononuclear cellsEar thicknessPhosphodiesterase 4Clinical developmentBroad-spectrum anti-inflammatory activityPDE4 inhibitorsEx vivoHuman peripheral blood mononuclear cellsTumor necrosis factor αSecond-generation PDE4 inhibitorsEar skin inflammationWhole bloodMarkers of inflammationAnti-inflammatory effectsInflammatory skin diseasePro-inflammatory cytokinesBlood mononuclear cellsNovel treatment optionsNecrosis factor αPre-clinical modelsAnti-inflammatory activitySelective PDE4 inhibitorLong-term managementPBMC production